2013-01-29 11:42:35 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Benitec Biopharma Ltd and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Benitec Biopharma Ltd (BLT). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Benitec Biopharma Ltd investor.
Report Summary: Benitec Biopharma Ltd is a low quality company with a neutral outlook. Benitec Biopharma Ltd has weak business growth and is run by inefficient management. The trend in Benitec Biopharma Ltd fair value exchange rate against its closest rated-competitor, Circadian Technologies Limited, has been appreciating over the past 2 weeks. When compared to its closest competitor, Benitec Biopharma Ltd shows less overvaluation and is equally likely to underperform the market.
The 3-page report breaks down the Total StockMark into its three
components – business, management and price, performing an in-depth analysis of Benitec Biopharma Ltd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.